Observational Study of KRAS-variant and microRNA Binding Site Mutations in Cancer
This observational study is looking at how certain genetic changes, called KRAS-variant and other microRNA binding site mutations, might be linked to cancer risk, prevention, and treatment. Researchers will test your saliva for the KRAS-variant. They want to understand how common the KRAS-variant is in certain groups, like people with breast cancer who don't have BRCA mutations. They also want to see how different treatments affect people with and without the KRAS-variant. You might be able to join if you are 18 or older and have a personal or family history of cancer, endometriosis, or an autoimmune disease. The study is currently recruiting a large number of participants, up to 15,000 people.
- Study design
- This is an observational study planning to enroll up to 15,000 participants. It will measure the prevalence of the KRAS-variant and compare the impact of interventions in different groups.
- What's involved
- You would provide a saliva sample for genetic testing and answer questionnaires about lifestyle factors on an ongoing basis.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure outcomes, such as the prevalence of the KRAS-variant and the impact of interventions, at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joanne Weidhaas, MDPhD · PRINCIPAL_INVESTIGATOR · MiraKind
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Measuring the prevalence of the KRAS-variant in certain populations Prevalence of the KRAS-variant in BRCA negative breast cancer patients1 year
The Prevalence of the KRAS-variant will be determined in specific populations, such as women with drug resistant endometriosis, or BRCA negative breast cancer. The prevalence will be compared to extensive data on the expected and known prevalence of the KRAS-variant in non-diseased populations. Statistical significance will be determined by Chi-squared analysis.
- Comparing the impact of interventions in KRAS-variant versus non-KRAS variant populations1 year
We will compare the impact of specific treatment approaches for example in women with the KRAS-variant and double primary breast cancer, versus the interventions used in non-KRAS-variant double primary breast cancer patients.